Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 276

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 276
---
 event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex
Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work.

Each party under the
Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1) such party’s
breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2) the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex
Master Services Agreement.

179

The foregoing is a summary of the material terms of the Tulex Master Services Agreement in
the form filed as an exhibit to the registration statement of which this prospectus is a part. You should read the form of the agreement for a complete understanding of all of its terms.

Intellectual Property

Our success
depends in part on our ability to obtain and maintain proprietary protection for our drug products, product candidates, and related technology and know-how, to operate without infringing the proprietary rights
of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of
the United States related to our novel adhesion and delivery technology, inventions, improvements, drug products, and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to
cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our novel adhesion and delivery technology, platforms and product candidates.

Generally, patents are granted a term of 20 years from the earliest claimed non-provisional filing
date. In certain instances, the patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We
cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates.

Our patent portfolio, consisting of owned and/or licensed IP as